drugset

drugset / Trial / NCT06078839

Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy

NCT06078839 ↗

Phase 4 Not yet recruiting 778 enrolled Xu Li Affiliated Hospital of Nantong University · collab Anhui Provincial Hospital · collab Benxi Cental Hospital · collab Dalian NO.3 People's Hospital · collab First Affiliated Hospital of Gannan Medical University · collab First Affiliated Hospital of Xinjiang Medical University · collab Genertec Liaoyou Gem Flower Hospital · collab Hohhot First Hospital · collab Huludao central hospital · collab Jiangxi Provincial People's Hopital · collab Jilin University · collab LanZhou University · collab Liaoyang City Central Hospital · collab Northern Jiangsu People's Hospital · collab Second Affiliated Hospital of Xi'an Jiaotong University · collab Shanxi Bethune Hospital · collab Shanxi Provincial People's Hospital · collab Shenyang Sixth People's Hospital · collab The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · collab The First Affiliated Hospital of Liaoning · collab The First Affiliated Hospital of Ningbo · collab The First Affiliated Hospital of Suzhou Medical · collab The First Affiliated Hospital of Wenzhou · collab The First Affiliated Hospital of Xinjiang · collab The Fourth Affiliated Hospital of China Medical · collab The Second Hospital University of South China · collab The Tenth People's Hospital of Shenyang · collab Tianjin Medical University General Hospital · collab Tianjin Third Central Hospital · collab Tongji Medical College of Huazhong University · collab Zhejiang Hospital · collab Zhejiang Provincial People's Hospital · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study was to evaluate the therapeutic effect of nafamostat mesilate on patients with severe infection-related coagulation。

Timeline

Start: 2023-10-01
Primary completion: 2026-10-01
Completion: 2026-10-01

Publications

Yang H, Feng J, Ma Y, Ma X, Li X; EASNMS investigators. Efficacy and safety of nafamostat mesilate for sepsis (EASNMS): study protocol for a multicenter randomized controlled trial. Trials. 2025 Jul 29;26(1):262. doi: 10.1186/s13063-025-08979-4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nafamostat	Small molecule	2 mg/kg	Intravenous

Indications